{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:59:58Z","timestamp":1787857198411,"version":"build-2784847793"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>Toripalimab is the first antitumor programmed cell death protein 1 (PD-1) antibody approved in China. For better patient management, it is important to understand the real-world outcomes of toripalimab in treating patients with lung cancer in the real world outside of clinical trials to improve patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively examined the clinical data of 80 patients with lung cancer who received the PD-1 inhibitor (toripalimab). The Chi-square test was performed to identify clinical factors associated with the advancement of the disease. Multivariate Cox regression analysis was used to screen prognostic variables linked to real-world progression-free survival (PFS) and overall survival (OS). OS and PFS were calculated using the Kaplan-Meier method, and the comparisons were determined using the log-rank test, and continuous and categorical variables were explained using median and percentage, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>\n                      The median OS of the estimated 80 patients was 15.85 months (95% confidence interval [CI]: 14.103\u201317.949 months), and the estimated PFS was 5.650 months (95% CI: 7.226\u201311.264 months). The longer OS and PFS correlate with the patient\u2019s staging and number of treatment lines. The PD-1 drug gave stage III patients a significantly longer PFS and OS compared to stage IV patients (PFS: 14.65 vs. 6.68,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004; OS: 21.1 vs. 13.7,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). First- or second-line immunotherapy patients have significantly longer PFS and OS than third- or fourth-line (PFS: 6.4 vs. 3.6,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009; OS: 20.0 vs. 10.5,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). In patients with stage IV (n = 60) with extensive metastasis, the site of metastasis is mostly 1\u20133 sites after receiving toripalimab. The duration of PD-1 inhibitor OS in progressive patients (n = 56) was significantly prolonged (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.038).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>For patients with lung cancer, toripalimab can considerably extend PFS and OS in the first or second line and in stage III. PD-1 inhibitors are administered to patients with stage IV extensively metastatic lung cancer, which indicates an oligometastatic progression pattern, primarily in 1\u20133 locations, who are treated with PD-1 inhibitors. Continuing toripalimab beyond disease progression significantly prolonged OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_500_24","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:02:55Z","timestamp":1736510575000},"page":"2021-2028","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical features and prognosis analysis of stage III\/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective"],"prefix":"10.4103","volume":"20","author":[{"given":"Chenlin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, School of Clinical Medicine, Shandong Second Medical University, Weifang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Province Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Province Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2019nan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Province Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Province Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"R1-20250110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer:Current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R3-20250110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4103\/jcrt.JCRT_903_18","article-title":"Pembrolizumab for the treatment of nonsmall cell lung cancer:Current status and future directions","volume":"15","author":"Qin","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R4-20250110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/jcrt.jcrt_1523_23","article-title":"Immunosenescence and immunotherapy in older NSCLC patients","volume":"20","author":"Zhang","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R5-20250110","doi-asserted-by":"crossref","first-page":"730666","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab:The first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"R6-20250110","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors:Basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr Med Chem"},{"key":"R7-20250110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41392-021-00751-9","article-title":"Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC:A multicenter phase-II trial","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20250110","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors:Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R9-20250110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/jcrt.jcrt_1898_22","article-title":"Immune checkpoint inhibitors:Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST","volume":"20","author":"Yirgin","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R10-20250110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade:A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"R11-20250110","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.4103\/jcrt.jcrt_1456_21","article-title":"Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab","volume":"19","author":"Singla","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R12-20250110","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00262-021-03121-0","article-title":"A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer","volume":"71","author":"Zuo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R13-20250110","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.4103\/jcrt.JCRT_971_20","article-title":"Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment:A case report and literature review","volume":"16","author":"Yin","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R14-20250110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2020.1762561","article-title":"Toripalimab for the treatment of melanoma","volume":"20","author":"Tang","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R15-20250110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC):A single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R16-20250110","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma:A multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"R17-20250110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06):A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"R18-20250110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R19-20250110","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4103\/jcrt.jcrt_88_23","article-title":"An overview of current advances of PD-L1 targeting immuno-imaging in cancers","volume":"19","author":"Chen","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R20-20250110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"key":"R21-20250110","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"R22-20250110","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024):A multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"R23-20250110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.006","article-title":"Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer:A systematic literature review and network meta-analysis","volume":"177","author":"O'Byrne","year":"2023","journal-title":"Lung Cancer"},{"key":"R24-20250110","first-page":"1","article-title":"Immunotherapy in non-small cell lung cancer:Update and new insights","volume":"7","author":"Mielgo-Rubio","year":"2021","journal-title":"J Clin Transl Res"},{"key":"R25-20250110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","article-title":"Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R26-20250110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in nonsmall cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"R27-20250110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"R28-20250110","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.3390\/cancers12123729","article-title":"Primary and acquired resistance to immunotherapy in lung cancer:Unveiling the mechanisms underlying of immune checkpoint blockade therapy","volume":"12","author":"Boyero","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R29-20250110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","article-title":"Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment","volume":"46","author":"Wang","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"(Suppl 1)","key":"R30-20250110","doi-asserted-by":"crossref","first-page":"C32","DOI":"10.4103\/0973-1482.163836","article-title":"A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer","volume":"11","author":"Qi","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"R31-20250110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150):Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R32-20250110","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_500_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:39:29Z","timestamp":1787773169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_500_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_500_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-03-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}